Evidence map›Paper›PMID 36688641›Full record

ArticleMicrobiology spectrum2023

Test Performance and Potential Clinical Utility of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel.

T P McCarty, P Cumagun, J Meeder, D Moates, W S Edwards, J Hutchinson, R A Lee, S M Leal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

T P McCartyDepartment of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
P CumagunDepartment of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
J MeederUAB Fungal Reference Laboratory, Department of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
D MoatesUAB Fungal Reference Laboratory, Department of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
W S EdwardsDepartment of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
J HutchinsonUAB Fungal Reference Laboratory, Department of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
R A LeeDepartment of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-9701-8156
S M LealUAB Fungal Reference Laboratory, Department of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-6939-9572
University of Alabama at Birmingham · USUniversity of Alabama at Birmingham Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The test performance and potential clinical utility of the ePlex blood culture identification Gram-negative (BCID-GN) panel was evaluated relative to matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry on bacterial isolates and conventional antimicrobial susceptibility testing. The majority (106/108, 98.1%) of GN bacteria identified by MALDI were on the BCID-GN panel, and valid tests (107/108, 99.1%) yielded results on average 26.7 h earlier. For all valid tests with on-panel organisms, the positive percent agreement was 102/105 (97.2%) with 3 false negatives and the negative percent agreement was 105/105. Chart review (

Indexed as

Anti-Infective AgentsBacteremiaAnti-Bacterial AgentsBacteriaBlood CultureGram-Negative BacteriaHumansAnti-Bacterial AgentsAnti-Infective Agentsblood cultureGram negativemolecular diagnostics

Identifiers

PMID36688641
PMCPMC9927486
OpenAlexW4317752008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.